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The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line
treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24–79) years, World Health
Organisation performance status 0–2 and median four marker lesions, received irinotecan 180mgm
 2 on day 1, oxaliplatin 85–
100mgm
 2 on day 15 and UFT 200–300mgm
 2 day
 1 with LV 90mgday
 1, days 1–21 of a 28-day cycle. Patients were treated in
cohorts of three. At the highest dose (irinotecan 180mgm
 2, oxaliplatin 100mgm
 2 and UFT 300mgm
 2 day
 1), three of four
patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2
toxicities at the maximum tolerated dose (irinotecan 180mgm
 2, oxaliplatin 100mgm
 2 and UFT 250mgm
 2 day
 1). There were
no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free
survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for
patients with advanced colorectal cancer. We recommend a dose of irinotecan 180mgm
 2 on day 1, oxaliplatin 100mgm
 2 on day
15 and UFT 250mgm
 2 day
 1 with LV 90mgday
 1 on days 1–21 of a 28-day cycle for future studies.
British Journal of Cancer (2007) 96, 38–43. doi:10.1038/sj.bjc.6603521 www.bjcancer.com
& 2007 Cancer Research UK
Keywords: advanced colorectal cancer; CPT-11; irinotecan; oxaliplatin; tegafur–uracil; UFT
                                           
The lifetime risk of developing colorectal cancer is one in 20 in the
UK (Office for National Statistics, 2004). Around 31000 cases are
diagnosed annually and over 18000 patients die as a result of the
disease, making colorectal cancer the second most common cause
of cancer death. For patients with unresectable local or metastatic
disease, either at the time of presentation or at relapse (collectively
termed ‘advanced disease’), the prognosis is poor. Since the advent
of 5-fluorouracil (5-FU) in the treatment of colorectal cancer
nearly 50 years ago, subsequent refinement of administration
regimens for use in such patients have only improved their median
survival from 6 to 9 months to approximately 12 months (Quinn
et al, 2001). The aim of treating these patients is, therefore, to
improve both the duration and quality of their remaining life.
5-Fluorouracil is now used in combination with newer drugs
that have nonoverlapping mechanisms of action and hence no
crossresistance with 5-FU. One such agent is irinotecan, a
topoisomerase I inhibitor that has been shown to improve
response rates, increase median times to progression and
treatment failure, and provide significant survival benefits when
used in combination with 5-FU/leucovorin (LV) compared with
5-FU/LV alone (Douillard et al, 2000; Saltz et al, 2000). Oxaliplatin
(Wiseman et al, 1999) is also active in colorectal cancer and
response rates of 40–50% have been demonstrated for the
combination of oxaliplatin and 5-FU/FA (de Gramont et al, 2000;
Giacchetti et al, 2000).
The oral fluoropyrimidines UFT (tegafur:uracil in a 4:1 ratio)
and capecitabine are more convenient and acceptable forms of
chemotherapy than intravenous 5-FU and have been shown to
have equivalent efficacy to intravenous bolus 5-FU plus LV in two
randomised studies (Carmichael et al, 2002; Douillard et al, 2002).
In addition, UFT appears to have a more favourable toxicity profile
than bolus 5-FU-based regimens and UFT has also been shown to
be more acceptable than intravenous 5-FU in terms of patient
preference (Borner et al, 2002). Both irinotecan and oxaliplatin
have been used in combination with UFT in the treatment of
patients with colorectal cancer, and have demonstrated promising
activity and tolerability (Alonso et al, 2003; Bennouna et al, 2006).
A challenge facing physicians is that only about 50% of patients
who receive first-line therapy are well enough to receive second-
line chemotherapy (de Gramont et al, 2000; Douillard et al, 2000;
Giacchetti et al, 2000; Saltz et al, 2000). One way forward,
therefore, might be to combine a fluoropyrimidine with both
oxaliplatin and irinotecan in the first-line setting so that a patient
receives all three drugs ‘up front’. Previous studies of irinotecan
and oxaliplatin with 5-FU have reported high response rates and
impressive survival times (Falcone et al, 2002; Souglakos et al,
2006), suggesting that further investigation of concurrent admin-
istration of all three drugs is warranted in the first-line manage-
ment of patients with metastatic colorectal cancer.
We undertook the present dose-finding study of UFT with LV
plus alternating irinotecan and oxaliplatin with the aim of
maintaining the efficacy demonstrated in previous 5-FU studies
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swhile improving the convenience and acceptability of the
treatment by using UFT instead of intravenous 5-FU. We
hypothesised that patients would benefit from receiving three of
the most active drugs available for the treatment of this disease ‘up
front’, as soon as they present with metastatic disease. By
alternating the use of oxaliplatin and irinotecan, we hoped that
patients would recover fully from the side effects of each drug
before it was administered again. We also felt that it would be
possible to increase the dose of oxaliplatin in an attempt to
increase the efficacy of this regimen.
MATERIALS AND METHODS
Patient selection
Patients were eligible for inclusion in this single-centre, phase I
open-label dose-finding trial if they had histologically confirmed
advanced adenocarcinoma of the colon or rectum, with inoperable,
measurable metastatic disease and no prior history of chemother-
apy for metastatic disease other than adjuvant bolus 5-FU, which
was permitted if administered more than 6 months before entry
into this trial. Other selection criteria included age X18 years,
World Health Organisation performance status (PS) 0–2 and life
expectancy 43 months. All patients were required to have
adequate haematological function (neutrophil count X1.5 10
9
l
 1 and platelet count X150 10
9l
 1), hepatobiliary function
(serum bilirubin p1.5 upper limit of normal [ULN]; ALP
p5 ULN; transaminase (AST or ALT) p3 ULN) and adequate
renal function (estimated Cockcroft clearance X50mlmin
 1,o r
measured glomerular filtration rate [EDTA or creatinine clearance]
in the normal range).
Patients were excluded if they had a concurrent uncontrolled
medical illness or other previous or current malignant disease
likely to interfere with protocol treatments. Patients could not have
brain metastases, partial or complete bowel obstruction, chronic
diarrhoea or inflammatory bowel disease, any confirmed abnorm-
ality of biliary transport, previous transplantation surgery or a
recent history of uncontrolled angina or cardiac arrhythmias.
Other excluded patient groups were pregnant or lactating women,
patients on halogenated antiviral drugs or cytochrome P450
inhibitors and patients with a prior history of radiotherapy to
the abdomen or pelvis.
The trial was conducted with full local ethical committee
approval, according to the accepted standards of good clinical
practice, and in agreement with the latest version of the
Declaration of Helsinki. Written informed consent was a
prerequisite for all patients. Pretreatment baseline evaluations
included a complete medical history and physical examination
(including weight and PS), full blood count and biochemistry
including carcinoembryonic antigen (CEA) and radiological
assessment with a computed tomographic scan.
Treatment and dose escalation
Patients were assessed every 14 days when they attended for
chemotherapy. Their PS and weight were noted and any toxicities
recorded according to the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 2. A full blood count and
biochemistry profile was also performed. The CEA assessment was
repeated if the level was raised at baseline.
Treatment was initiated within 4 weeks of the investigations that
were used for eligibility determination and disease evaluation. All
patients received irinotecan 180mgm
 2 as a 90-min infusion on
day 1 of the 28-day cycle, and were given UFT capsules (each
containing tegafur 100mg and uracil 224mg) to take orally in
combination with LV 90mgday
 1 three times daily on days 1–21,
at a starting dose of 200mgm
 2day
 1. Patients returned on day 15
for a 2-h infusion of oxaliplatin at a starting dose of 85mgm
 2.
Patients were recruited sequentially in cohorts of three and there
was no intra-patient dose escalation. The planned dose escalation
schedule is shown in Table 1.
If no grade 3 or 4 toxicity (other than alopecia) was encountered
by the end of the first cycle, further patients were entered at the
next dose level. If one or more patients developed grade 3/4
non-haematological toxicity, a further three patients were added to
this cohort. Similarly, if one or more patients developed grade 4
haematological toxicity (other than anaemia), then a further three
patients were added to this cohort. If there were no more episodes
of grade 3/4 toxicity, then further patients were entered at the next
dose level. When at least two out of six patients at the same dose
level developed a significant toxicity, this was considered to be a
dose-limiting toxicity (DLT) and the dose was the maximum
administered dose; the level below this was therefore considered
the maximum tolerated dose (MTD). If all patients in a cohort of
three developed significant haematological or non-haematological
toxicity, treatment was stopped and the dose level below was taken
as the MTD.
Chemotherapy was administered for at least 8 weeks before
reassessment of measurable metastatic disease by the Response
Evaluation Criteria in Solid Tumours [RECIST] (Therasse et al,
2000), unless a criterion for study discontinuation was met.
Patients with stable disease or a response continued treatment
until there was clinical or radiological evidence of disease
progression or the occurrence of unacceptable or cumulative
toxicity. Treatment was stopped at the request of the patient for
any reason or if, in the opinion of the investigator, it was in the
patient’s best interests to do so. Patients received 2 months of
treatment initially and a further two periods of 2 months if the
patient had stable disease or better on tumour assessment. Selected
patients could receive treatment beyond a total of 6 months (until
disease progression) at the discretion of the investigator and in
agreement with the individual patient.
Prophylactic anti-emetics (dexamethasone 8mg and ondanse-
tron 8mg) were administered intravenously with the irinotecan
and oxaliplatin infusions and orally for 48h afterwards. Delayed
diarrhoea was treated early and aggressively with loperamide, with
the addition of oral ciprofloxacin if it persisted for more than 24h.
Dose adjustments
On days 1 and 15, if Xgrade 2 neutropaenia or platelets
o100 10
9l
 1 (o 75 10
9 for oxaliplatin), all chemotherapy
was delayed by 1 week. If 41 delay, or 1 delay of X2 weeks
occurred, the dose of irinotecan and oxaliplatin was reduced by
20% and UFT by one capsule (100mg). This was continued at the
lower dose for subsequent cycles unless further toxicity occurred.
If a further delay for myelotoxicity occurred despite this dose
reduction, a 50% reduction of the original dose of irinotecan and
oxaliplatin was made if the patients’ PS had not decreased. If this
had occurred, withdrawal of the patient from this study was
considered.
Table 1 Dose
a escalation cohorts
Cohort
UFT
(mgm
 2day
 1)
Irinotecan
(mgm
 2day
 1)
Oxaliplatin
(mgm
 2day
 1)
1 200 180 85
2 250 180 85
3 250 180 100
4 300 180 100
aDoses were calculated using the patient’s body surface area with no upper limit. UFT
was administered on days 1–21 of the 28-day cycle; irinotecan was administered on
day 1 and oxaliplatin was administered on day 15.
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sAfter an episode of severe diarrhoea (grade 3–4), chemotherapy
was delayed until full recovery and resumed at irinotecan doses
reduced by 20% and UFT reduced by one capsule. If diarrhoea
from the previous cycle, even if not severe, had not resolved by the
time the next cycle was due, treatment was delayed by 1 week. If
further Xgrade 3 diarrhoea occurred, irinotecan was reduced to
50% of the original dose and UFT reduced by two capsules. Grade
3 of above parasthesia of hands and feet and dysaesthesia in the
throat, particularly in the cold, if persisting for 28 days (i.e., until
the next cycle was due), led to omission of oxaliplatin from the
regimen.
If hepatobiliary or renal function deteriorated below eligibility
criteria limits during treatment, the irinotecan and/or oxaliplatin
dose was adjusted as shown in Table 3. Any significant
deterioration in liver function tests or renal glomerular filtration
rate was promptly investigated by ultrasound examination to
exclude progressive disease and also to look for possible
reversibility of biliary tract or ureteric obstruction by stenting or
percutaneous diversion.
RESULTS
Twenty-five patients were entered into the study between February
2004 and April 2005. Patient demographics and clinical character-
istics at baseline are shown in Table 2.
Response
Twenty-one out of 25 patients were evaluable for response. Four
out of 25 patients were not assessable for response. The first
patient (dose level 1) died after only one dose of irinotecan and
thus was not evaluable. Two patients received only one cycle of
treatment before withdrawing from the study for psychosocial
reasons; these patients were thus not assessable for response. One
further patient (dose level 4) received only one dose of irinotecan
and withdrew after being admitted to hospital with grade 3
abdominal pain.
Fifteen patients achieved a partial response (71%) and one
patient underwent a partial hepatectomy. Two patients had stable
disease and the clinical benefit to this cohort was 81% (complete
responseþpartial responseþstable disease). Four patients had
progressive disease during treatment. Responses according to the
individual dose levels are shown in Table 4. The median
progression-free survival (PFS) was 268 days (8.8 months) (95%
confidence interval 192–340 days (6.3–11.2 months)); overall
survival data are too immature to be reported.
Toxicity
Six patients were entered at dose level 1 and toxicity was assessed
within the first month of treatment and used to dictate dose
escalation (Table 5). The total number of cycles received at each
dose level, together with dose reductions and delays, are detailed in
Table 6. A total of 113 doses of irinotecan therapy were given to 25
patients. Thirty doses were reduced by 20% and one by 50%.
Accordingly, 113 courses of UFT were prescribed, 27 of which were
reduced by one capsule and one of which was reduced by two
Table 2 Patient characteristics at baseline
No. of patients 25
Median age, years (range) 63 (24–79)
Sex, no. of male/female subjects 18/7
Primary tumour site, no. of patients
Colon 13
Rectum 6
Rectosigmoid 6
WHO performance status, no. of patients
07
11 6
22
Prior surgical resection, no. of patients
Radical 8
Palliative 5
Defunctioned only 1
None 11
Sites of metastatic disease, no. of patients
Liver only 10
LN only 1
Liver and lung 3
Liver and LN 1
Lung and LN 2
Liver, lung and LN 4
Pelvic disease only 2
Pelvic and liver 1
Pelvic and LN 1
No. of measurable lesions (no. of patients)
13
21
X32 1
LN¼lymph node; WHO¼World Health Organisation.
Table 3 Dose adjustments
Day 1 and 15 lab
values
Irinotecan
(%)
Oxaliplatin
(%) Uft (%)
Bilirubin
a ALP
a
o1.5 n o5 n 100 100 100
1.5–3 n 45 n 50 100 Omit
43 n — Omit Omit Omit
Cockcroft (GFR; mlmin
 1)
b
450 100 100 100
30–50 100 50 100
o30 50 Omit 1 cap
reduction
c
aDeteriorating liver function during treatment could indicate progressive disease or
biliary obstruction and was investigated by ultrasound examination.
bDeteriorating
renal function during treatment could indicate progressive pelvic disease and ureteric
obstruction and was investigated by ultrasound examination.
cUFT is available in
100mg capsules. All calculated doses were rounded to the nearest no. of capsules.
Table 4 Antitumour efficacy
Dose
level 1
Dose
level 2
Dose
level 3
Dose
level 4 Total
Response (n¼6) (n¼6) (n¼9) (n¼4) (n¼25)
Complete response
(CR)
0 000 0
Partial response (PR) 2 4 7 2 15
Stable disease (SD) 1 0 1 0 2
Progressive disease 2 1 0 1 4
Not assessable 1 1 1 1 4
Objective response
rate
a
71%
Clinical benefit
(CR+PR+SD)
a
81%
a21 evaluable patients.
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scapsules as per protocol. A total of 94 doses of oxaliplatin
chemotherapy were administered, of which seven doses were
reduced by 20%. The dose intensity for this regimen is shown in
Table 7.
The first patient entered into the study was a young woman with
poor performance status (PS 2) and multiple sites of disease. This
patient developed grade 3 diarrhoea, nausea and lethargy soon
after receiving the first cycle of treatment and was admitted to
hospital. She developed grade 4 neutropaenia and died suddenly.
There were no subsequent occurrences of grade 3 or 4 toxicities
within the first month of therapy. One patient at dose level 1 died
suddenly in the third month of treatment as a result of a cardiac
abnormality. He had no prior cardiac history and no symptoms of
angina during the chemotherapy. This death was considered to be
either incidental or due to fluoropyrimidine-induced vascular
spasm. The second cohort of patients was treated with the same
dose of irinotecan and oxaliplatin but with an increased dose of
UFT (250mgm
 2). One patient in this group experienced grade 3
diarrhoea; a total of six patients were thus entered at this dose
level. Four patients were then entered at dose level 3 and received
an increased dose of oxaliplatin (100mgm
 2). One of these
patients complied poorly and received only one cycle of treatment,
necessitating their replacement with a fourth patient. No grade 3/4
toxicities were evident at this dose level.
The first patient treated at dose level 4 (UFT 300mgm
 2)
developed multiple grade 3 toxicities on completion of the first
cycle of treatment. A total of six patients were scheduled for entry
at dose level 4, but each of the first four patients treated at this
dose level suffered multiple grade 2 toxicities and a further two
patients experienced a grade 3 toxicity. Further recruitment at this
dose level was therefore stopped. The DLTs were lethargy,
diarrhoea and vomiting. Dose level 3, that is irinotecan
Table 5 Worst toxicity per patient (all cycles) by dose level
Dose level
1( n¼6) 2 (n¼6) 3 (n¼9) 4 (n¼4)
NCI-CTC grade 2 3 4234234234
Anaemia 1 1 2 1
Leucopaenia 1 2
Neutropaenia 1 1 1
Thrombocytopaenia 1
Alopecia 1
Anorexia 1
Lethargy 2 1 2 4 2 1
Nausea 1 1 1 1 1
Vomiting 1 1 1 1 1
Diarrhoea 2 2 3 1 1 1 3
AST 2
Neuropathy 1
Infection 1
Abdominal pain 1 1
Cardiac 1
AST¼aspartate aminotransferase; NCI-CTC¼National Cancer Institute Common Toxicity Criteria.
Table 6 Number of cycles given, number of dose reductions and delays
Irinotecan cycles Oxaliplatin cycles UFT cycles
Dose
level
No. of
patients Total
Median
(range) 20% DR 50% DR Total
Median
(range) 20% DR 50% DR Total
Median
(range)
1
capsule
DR
a
2 capsules
DR
a
Delays
Weeks
1 6 22 3 (1–6) 4 0 17 2 (0–6) 0 0 22 3 (1–6) 3 0 3
2 6 27 6 (1–6) 13 0 23 4 (1–6) 2 0 27 6 (1–6) 10 0 5
3 9 46 6 (1–6) 2 0 43 6 (0–6) 3 0 46 6 (1–6) 3 0 4
4 4 18 5.5 (1–6) 11 1 11 3 (0–5) 2 0 18 5.5 (1–6) 11 1 3
Total 25 113 — 30 1 94 — 7 0 113 — 27 1 15
aEach UFT capsule contained tegafur 100mg and uracil 224mg. DR: dose reduction.
Table 7 Median dose intensity (%) over two, four and six cycles
Two cycles Four cycles Six cycles
Dose level Irinotecan Oxaliplatin Irinotecan Oxaliplatin Irinotecan Oxaliplatin
1 100 98.2 89.6 92.1 89.5 94.5
2 100 100 82.8 82 81.8 92.3
3 100 100 100 100 100 100
4 80 66.7 85 56 85.9 62.6
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s180mgm
 2, oxaliplatin 100mgm
 2and UFT 250mgm
 2, was
considered to be optimal and this dose level was expanded with
a further five patients (nine patients in total). There were no grade
3 or 4 toxicities resulting from the first cycle of treatment at this
dose level; however, two patients developed grade 3 toxicity with
prolonged administration of chemotherapy (see Table 5).
With regard to neurotoxicity, 15 out of 25 patients developed
grade 1 toxicity during therapy and one patient (dose level 3)
experienced grade 3 toxicity during cycle 2, which necessitated a
20% reduction in the oxaliplatin dose for all subsequent cycles.
There was no evidence of grade 2 or higher hand–foot syndrome
or stomatitis.
DISCUSSION
This phase I study has shown that the combination of UFT,
irinotecan and oxaliplatin is a well-tolerated and efficacious first-
line treatment for patients with metastatic colorectal cancer. Thus
far we have shown an objective response rate of 71% and disease
stabilisation in a further 10% of patients. One patient underwent a
partial hepatectomy. As expected, the DLTs were lethargy, nausea
and diarrhoea. There were no cases of hand–foot syndrome at any
dose level, which underlines an advantage of UFT over continuous
5-FU regimens or capecitabine.
The response rate observed in our study was higher than that
reported in a previous study of the combination of UFT, irinotecan
and oxaliplatin in the first-line setting. In the study by Petrioli et al
(2004), a fixed dose of UFT (250mgm
 2day
 1) was given for 28
days of a 35-day cycle, with oxaliplatin (85mgm
 2) on days 1 and
15 of odd numbered cycles and irinotecan (180mgm
 2) on days 1
and 15 of even numbered cycles. An objective response rate of
58.5% was achieved using this regimen and diarrhoea was the most
common grade 3 toxicity, occurring in 29% of patients. We
employed a higher dose intensity for both irinotecan and
oxaliplatin, and achieved an improved response rate with an
equally acceptable level of toxicity. The alternating use of
oxaliplatin and irinotecan was deliberately chosen in our study
to allow patients to recover fully from the side effects of one agent
before it was administered again. Using this approach, we were
able to increase the dose of oxaliplatin to 100mgm
 2 in an attempt
to increase the efficacy of this regimen within the limits of
tolerability. Dose-limiting neurotoxicity, including hand–foot
syndrome, was not encountered during dose escalation and only
one patient had grade 3 neurotoxicity at the MTD that required a
dose reduction during the second treatment cycle.
Previous studies have examined the efficacy of concurrent
treatment with irinotecan and oxaliplatin with 5-FU rather than
UFT. Souglakos et al (2006) reported a 57% response rate when
irinotecan and oxaliplatin were given ‘up front’ with 5-FU to a
cohort of 57 patients. Falcone et al (2002) reported a higher
response rate (71%) using a similar combination, as well as a 26.5-
month overall survival and a 10.4-month PFS, which was
comparable with the 8.8 months observed in our study. To our
knowledge, there are no published studies combining irinotecan
and oxaliplatin concurrently with the other major oral fluoro-
pyrimidine, capecitabine, as a first-line treatment. There have
been, however, a number of other phase I and II trials presented in
abstract form using this triplet combination as a 3-week schedule,
but the doses of each of the drugs varies widely between trials.
Maroun et al (2006) reported early findings of a dose-escalation
study for first-line treatment of metastatic colorectal cancer
starting at irinotecan 180mgm
 2 day 1, oxaliplatin 85mgm
 2
day 1 and capecitabine 850mgm
 2 bid days 2–15, and discovered
febrile neutropaenia to be the main DLT, but the MTD had not
been reached.
While it is important not to over-interpret results from these
studies, the response rates and median survival times suggest that
further investigation of this ‘up front’ approach is warranted in
patients with metastatic colorectal cancer, many of whom will not
have the opportunity to receive a second-line treatment. While
some patients may not be offered further treatment after the failure
of first-line therapy and others may refuse it, the majority will have
deteriorated clinically with disease progression during the first-
line therapy to such an extent that they are unfit for further
chemotherapy. Administering all three drugs ‘up front’ to patients
with advanced colorectal cancer therefore maximises their chances
of benefiting from three of the most active agents available for the
treatment of this disease.
One possible criticism of this approach to treatment may be that
patients who receive all three drugs in the first-line setting have
limited possibilities for second-line therapy. On the other hand, it
can be argued that this approach allows the rapid identification of
patients with chemoresistant disease without the need for multiple
levels of therapy. In addition, several options remain for second-
line therapy, including rechallenge with concurrent oxaliplatin,
irinotecan and UFT for patients who previously responded,
treatment with the antiepidermal growth factor antibody cetux-
imab plus irinotecan (Cunningham et al, 2004) treatment with a
combination of Mitomycin C and capecitabine or FOLFOX and
bevacizumab (Giantonio et al, 2005) if parasthesia is not
significant.
In conclusion, we have established from this phase I study an
MTD of irinotecan 180mgm
 2 on day 1, oxaliplatin 100mgm
 2
on day 15 and UFT 250mgm
 2day
 1 with LV 90mgday
 1 on days
1–21 of a 28-day cycle for the first-line treatment of metastatic
colorectal cancer. This combination, which provides a high
response rate, prolonged PFS and a good side-effect profile, is
being investigated as part of an ongoing phase II trial.
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